ADC – ANTIBODY-DRUG CONJUGATES IN ONCOLOGY
Background: Antibody-drug conjugates (ADC) are a promising novel therapy for oncology patients as it combines tumor- targeted antibodies with cytotoxic molecules resulting in improved therapeutic outcomes. Aim: The aim of this article is a thorough analysis of ADC possibilities in oncology focusing on treatment options, side effects of therapies for breast, bladder and lung cancers. Material and methods: A search of relevant research databases was conducted to identify eligible papers. Results: Findings reveal ADC to be a promising treatment option as a innovative, more precise form of therapy.
Authors
- Jakub Senko
- Joanna Kulpa (ORCID: https://orcid.org/0009-0007-7057-6282)
- Marcin Szczepanik (ORCID: https://orcid.org/0009-0004-0475-6187)
- Zofia Suchanek (ORCID: https://orcid.org/0009-0003-6911-230X)
- Wojciech Pociej
- Krzysztof Dzierbunowicz (ORCID: https://orcid.org/0009-0007-9203-7706)
- Dominik Szymczak (ORCID: https://orcid.org/0009-0008-5289-978X)
- Olaf Zołotar (ORCID: https://orcid.org/0009-0002-3084-9753)
- Jędrzej Kowalski (ORCID: https://orcid.org/0009-0005-5598-3707)
- Natalia Pociej (ORCID: https://orcid.org/0009-0003-9742-6760)
Institutions
- University of Szczecin (PL)
- Pomeranian Medical University (PL)
Publication Details
- Journal
- International Journal of Innovative Technologies in Social Science
- Published
- 2026-09-14
- DOI
- https://doi.org/10.31435/ijitss.3(51).2026.6657
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00